KATIE DAVIS: Open Payments
NPI 1669903084 · DOUGLAS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,615 in 55 payments from 14 companies in 2025. Trend: 2023 $1,952 · 2024 $2,055 · 2025 $1,615
Food & beverage: $1,615
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $276 |
| AstraZeneca Pharmaceuticals LP | 9 | $251 |
| ABBVIE INC. | 9 | $219 |
| PFIZER INC. | 7 | $204 |
| Corcept Therapeutics | 5 | $195 |
| Novo Nordisk Inc | 6 | $189 |
| GlaxoSmithKline, LLC. | 5 | $105 |
| Otsuka America Pharmaceutical, Inc. | 2 | $51 |
| Axsome Therapeutics, Inc. | 1 | $33 |
| Amgen Inc. | 2 | $31 |
Products named: CAPLYTA, VRAYLAR, Korlym, NURTEC ODT, Wegovy, FARXIGA, BREZTRI, TRELEGY ELLIPTA.
Industry payments across GA — which companies pay providers there.
